Logo
TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET ANALYSIS
  2. / Market Insights
  3. Transthyretin Amyloid Cardiomyopathy Treatment Market Analysis
We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET ANALYSIS

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type (Hereditary Transthyretin Amyloidosis (hATTR), Wild Type Transthyretin Amyloidosis (wtATTR)), By Drug Type (Transthyretin Stabilizers, Nonsteroidal Anti-Inflammatory Drugs (NSAID), RNAi Therapy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

  • Published In : Oct 2023
  • Code : CMI4321
  • Pages :160
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Leading Companies

Key Companies Insights

  • Major players operating in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market include Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Press Release

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market To Surpass US$ 11.23 Bn By 2030
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.